Replies to post #65063 on Anavex Life Sciences Corp (AVXL)

[JB3729]

It sounds like excellent 12 week data news to me. I have a great deal of confidence that AVXL will be awarded a late breaking oral presentation time slot in the near future!

Does dose-dependent cognitive improvement in MMSE and other cognitive markers not sounds like good news to you? We already know half the data at least in ADCS-ADL is exceptional. If none of that is good news to you, your standards are not realistic. Donepezil is not an effective SOC.

New Exploratory Alzheimer’s Drug Anavex 2-73: Dose Dependent Clinical Cognitive Improvement Observed in Mini Mental State Examination (MMSE) and Other Cognitive Markers in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Patients
Metro Toronto Convention Centre Room: Hall D/E
P1-046